ArticleAmerican journal of translational research2018

Interleukin enhancer binding factor 2 is a prognostic biomarker for breast cancer that also predicts neoadjuvant chemotherapy responses.

Zining Jin et al.PubMed ↗Full text ↗

No numbers read from the abstract.